BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11497246)

  • 1. Targeting of LAK activity to CEA-expressing tumor cells with an anti-CEA scFv/IL-2 fusion protein.
    Liao S; Khare PD; Arakawa F; Kuroki M; Hirose Y; Fujimura S; Tomita Y; Kuroki M
    Anticancer Res; 2001; 21(3B):1673-80. PubMed ID: 11497246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model.
    Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y
    Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity.
    Arakawa F; Shibaguchi H; Xu Z; Kuroki M
    Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cDNA cloning and sequencing of a novel monoclonal antibody to carcinoembryonic antigen and construction of a mouse/human chimeric antibody.
    Shibaguchi H; Arakawa F; Imakiire T; Kuroki M; Kuroki M
    Anticancer Res; 2003; 23(6a):4383-8. PubMed ID: 14666725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal anti-idiotype antibody 6G6.C4 fused to GM-CSF is capable of breaking tolerance to carcinoembryonic antigen (CEA) in CEA-transgenic mice.
    Schwegler C; Dorn-Beineke A; Nittka S; Stocking C; Neumaier M
    Cancer Res; 2005 Mar; 65(5):1925-33. PubMed ID: 15753392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein.
    Pavoni E; Flego M; Dupuis ML; Barca S; Petronzelli F; Anastasi AM; D'Alessio V; Pelliccia A; Vaccaro P; MonteriĆ¹ G; Ascione A; De Santis R; Felici F; Cianfriglia M; Minenkova O
    BMC Cancer; 2006 Feb; 6():41. PubMed ID: 16504122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specifically targeted killing of carcinoembryonic antigen (CEA)-expressing cells by a retroviral vector displaying single-chain variable fragmented antibody to CEA and carrying the gene for inducible nitric oxide synthase.
    Khare PD; Shao-Xi L; Kuroki M; Hirose Y; Arakawa F; Nakamura K; Tomita Y; Kuroki M
    Cancer Res; 2001 Jan; 61(1):370-5. PubMed ID: 11196189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins.
    Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP
    Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Replacement of the constant region gene of a novel anti-CEA antibody and characterization of its biological activity].
    Huang J; Shibaguchi H; Masahide K
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Sep; 22(5):650-3. PubMed ID: 16948917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of interleukin 2 to human ovarian carcinoma by fusion with a single-chain Fv of antifolate receptor antibody.
    Melani C; Figini M; Nicosia D; Luison E; Ramakrishna V; Casorati G; Parmiani G; Eshhar Z; Canevari S; Colombo MP
    Cancer Res; 1998 Sep; 58(18):4146-54. PubMed ID: 9751627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
    Kuroki M; Hachimine K; Huang J; Shibaguchi H; Kinugasa T; Maekawa S; Kuroki M
    Anticancer Res; 2005; 25(6A):3725-32. PubMed ID: 16302732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
    Schirrmann T; Pecher G
    Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of interleukin-2 to human MK-1-expressing carcinoma by fusion with a single-chain Fv of anti-MK-1 antibody.
    Matsumoto H; Liao S; Arakawa F; Ueno A; Abe H; Awasthi A; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(4):2001-7. PubMed ID: 12174877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by soluble CEA.
    Lutterbuese R; Raum T; Kischel R; Lutterbuese P; Schlereth B; Schaller E; Mangold S; Rau D; Meier P; Kiener PA; Mulgrew K; Oberst MD; Hammond SA; Baeuerle PA; Kufer P
    J Immunother; 2009 May; 32(4):341-52. PubMed ID: 19342971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells.
    Shibaguchi H; Luo NX; Kuroki M; Zhao J; Huang J; Hachimine K; Kinugasa T; Kuroki M
    Anticancer Res; 2006; 26(6A):4067-72. PubMed ID: 17195459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.
    Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T
    Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA.
    Kuroki M; Arakawa F; Khare PD; Kuroki M; Liao S; Matsumoto H; Abe H; Imakiire T
    Anticancer Res; 2000; 20(6A):4067-71. PubMed ID: 11131674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IgG isotype conversion of a novel human anti-carcinoembryonic antigen antibody to increase its biological activity.
    Huang J; Shibaguchi H; Zhao J; Luo N; Kuroki M; Kinugasa T; Hirose Y; Yamada H; Kuroki M
    Anticancer Res; 2006; 26(2A):1057-63. PubMed ID: 16619506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific binding of baculoviruses displaying gp64 fusion proteins to mammalian cells.
    Ojala K; Mottershead DG; Suokko A; Oker-Blom C
    Biochem Biophys Res Commun; 2001 Jun; 284(3):777-84. PubMed ID: 11396970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.